BACTI_B: Strong Q4 EBITDA and cost discipline offset revenue declines; partnerships and pipeline expanded

About this update from Bactiguard Holding Ab

Q4 saw strong EBITDA growth and improved profitability, driven by an updated Zimmer Biomet agreement and cost reductions, despite lower full-year revenues from currency effects and discontinued business. Strategic partnerships expanded, and new therapeutic areas showed early promise.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bactiguard Holding Ab